Research News
View articles by month and year
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Aromasin Reduces Risk But Weakens Bones
Research shows that Aromasin is good at lowering breast cancer risk in high-risk postmenopausal women, but weakens bones.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Aromasin Helps Reduce Breast Cancer Risk in High-Risk Women
Research shows that the hormonal therapy Aromasin can lower risk in high-risk, postmenopausal women who've never been diagnosed with breast cancer.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Aromatase Inhibitor Before Surgery May Make Lumpectomy an Option
Many women diagnosed with hormone-receptor-positive, early-stage breast cancer for whom mastectomy was recommended may be candidates for lumpectomy after taking an aromatase inhibitor.
-
New Guidelines Prefer Aromatase Inhibitors Over Tamoxifen
The American Society of Clinical Oncology has issued new guidelines on taking hormonal therapy medicines after breast cancer surgery.
-
Same Outcomes for Women Who Take Aromasin for 5 Years or Switch After Taking Tamoxifen
The latest results from the TEAM trial show that women who took tamoxifen for 2.5 to 3 years and then switched to Aromasin for 2 to 2.5 years (for a total of 5 years of hormonal therapy) had the same risk of recurrence as women who took Aromasin for 5 years.
